Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
arcticnovartis
Wed, 11/12/2025 – 23:04
Read more about Novartis Phase III trial for next-gener…
Entries by arcticnovartis
Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan
arcticnovartis
Mon, 11/10/2025 – 15:33
Read more about Novartis opens new radioligand therapy manufacturing facility in California as par…
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
arcticnovartis
Tue, 11/04/2025 – 07:19
Read more about New Novartis data at ASN Kidney Week and AHA Scientific Sessions demon…
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
arcticnovartis
Wed, 10/29/2025 – 15:34
Read more about Novartis ianalumab first drug to reduce disease activity and patient burden in…
Novartis completes acquisition of Tourmaline Bio
arcticnovartis
Tue, 10/28/2025 – 15:04
Read more about Novartis completes acquisition of Tourmaline Bio
Basel, October 28, 2025 – Novartis today announced that it has successfully co…
Novartis announces expiration of Tourmaline Bio tender offer
arcticnovartis
Tue, 10/28/2025 – 07:28
Read more about Novartis announces expiration of Tourmaline Bio tender offer
Basel, October 28 2025 – Novartis tod…
Novartis verzeichnet im dritten Quartal solide Steigerungen beim Umsatz und operativen Kernergebnis sowie starke Fortschritte in der Pipeline; Prognose für das Geschäftsjahr 2025 bestätigt
arcticnovartis
Tue, 10/28/2025 – 07:02
Read more about Nov…
Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance
arcticnovartis
Tue, 10/28/2025 – 07:02
Read more about Novartis delivers solid sales and core operating income growth wi…
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
arcticnovartis
Sun, 10/26/2025 – 18:04
Read more about Novartis agrees to acquire Avidity Biosciences, an innovat…
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
arcticnovartis
Sun, 10/26/2025 – 18:03
Read more about Novartis agrees to acquire Avidity Biosciences, an innovat…